PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 255 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR Foodie Fridays: Watermelon Salad August 27, 2021 How Joining a Clinical Trial Helped Me Find Hope While Living... December 5, 2023 Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated... March 5, 2021 COVID-19: “The really hard part is we know what needs to... July 7, 2020 Load more HOT NEWS EMA Recommends Extension of Indications for Pirtobrutinib Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... EMA Recommends Extension of Indications for Inotuzumab Ozogamicin Women Under 35 More Likely to Have Their Breast Cancer Spread
